title: DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.
abstract: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T(1)-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
authors.affiliation: Imaging Science and Biomedical Engineering, University of Manchester, Oxford Road, Manchester M13 9PT, UK.james.o'connor@manchester.ac.uk
authors.forename: J P B
authors.initials: JP
authors.lastname: O'Connor
authors.forename: A
authors.initials: A
authors.lastname: Jackson
authors.forename: G J M
authors.initials: GJ
authors.lastname: Parker
authors.forename: G C
authors.initials: GC
authors.lastname: Jayson
mesh_terms: D020533:Angiogenesis Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D002986:Clinical Trials as Topic; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor